Ser2372

Site Information
stIIVsRsGEDEsQE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 460922

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	brain cancer ( 5 ) , glioblastoma ( 5 ) , glioma ( 5 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 1 ) , Jurkat (T lymphocyte) ( 2 ) , M059K (glial) ( 3 , 4 , 5 )

References
1	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
2	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
3	Stokes M (2006) CST Curation Set: 1614; Year: 2006; Biosample/Treatment: cell line, M059K/untreated; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
4	Stokes M (2006) CST Curation Set: 1123; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
5	Stokes M (2005) CST Curation Set: 912; Year: 2005; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info